{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:11:25Z","timestamp":1786637485987,"version":"build-2736575974"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In a recent study of women with postmenopausal osteoporosis, treatment with teriparatide for a median of 19 months increased bone mineral density and decreased the risk of vertebral and nonvertebral fractures. Using the same cohort, the current study evaluated the relationship between these therapeutic effects and the patient's baseline age, vertebral bone mineral density, and prevalent vertebral fractures. In women over 65 years of age, treatment resulted in a greater increase in vertebral bone mineral density than in younger women (treatment-by-age interaction, p = 0.037), but baseline age had no effect on the relative risk reduction for vertebral fractures (treatment-by-age interaction, p = 0.558). In women receiving placebo (with calcium and vitamin D), there was an inverse relationship between baseline vertebral bone mineral density and vertebral fracture risk. When compared across bone mineral density tertiles, the effects of teriparatide on the relative risk for developing new vertebral fractures and increase in vertebral bone mineral density did not differ significantly (p = 0.817 and p = 0.615, respectively). Teriparatide treatment significantly decreased vertebral fracture risk in patients with a vertebral bone mineral density T score of less than \u22123.3 or a score between \u22122.1 and \u22123.3 (p &amp;lt; 0.001 and p = 0.027, respectively) and showed a trend toward reduced fracture risk in the group with a T score greater than \u22122.1 (p = 0.115). Placebo-treated women with two or more prevalent vertebral fractures had a significantly greater risk of developing new vertebral fractures than women with zero or one prevalent vertebral fracture (p &amp;lt; 0.001). When compared within prevalent vertebral fracture subgroups, the effects of teriparatide on the relative risk for developing new vertebral fractures were similar. The results of this study indicate that teriparatide offers clinical benefit to patients across a broad range of age and disease severity.<\/jats:p>","DOI":"10.1359\/jbmr.2003.18.1.18","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T21:31:36Z","timestamp":1146087096000},"page":"18-23","source":"Crossref","is-referenced-by-count":199,"title":["The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis"],"prefix":"10.1093","volume":"18","author":[{"given":"Robert","family":"Marcus","sequence":"first","affiliation":[{"name":"Eli Lilly, Inc., Indianapolis, Indiana, USA"},{"name":"Department of Medicine, Stanford University, Stanford, California, USA"},{"name":"The Geriatrics Research, Education, and Clinical Center, Veterans Affairs Medical Center, Palo Alto, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Eli Lilly, Inc., Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Satterwhite","sequence":"additional","affiliation":[{"name":"Eli Lilly, Inc., Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Mitlak","sequence":"additional","affiliation":[{"name":"Eli Lilly, Inc., Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019165717700_bib1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00002512-199915050-00003","article-title":"Pharmacological management of osteoporosis in postmenopausal women: A comparative review","volume":"15","author":"Reid","year":"1999","journal-title":"Drugs Aging"},{"key":"2024013019165717700_bib2","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocrinol Rev"},{"key":"2024013019165717700_bib3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"2024013019165717700_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal","volume":"16","author":"Cosman","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019165717700_bib5","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019165717700_bib6","first-page":"S1;S414","article-title":"In primates, treatment with PTH (1\u201334), teriparatide, increases bone strength at trabecular bone sites without compromising the strength of cortical bone","volume":"14","author":"Turner","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2024013019165717700_bib7","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024013019165717700_bib8","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk for fractures in women with low BMD but without vertebral fractures","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"2024013019165717700_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"2024013019165717700_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"2024013019165717700_bib11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1359\/jbmr.2002.17.7.1151","article-title":"Commentary on clinical safety of recombinant human parathyroid hormone (1\u201334) in the treatment of osteoporosis in postmenopausal women and in men","volume":"17","author":"Tashjian","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2024013019165717700_bib12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2024013019165717700_bib13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/(SICI)1097-0258(19970830)16:16<1889::AID-SIM607>3.0.CO;2-V","article-title":"Comparative calibration without a gold standard","volume":"16","author":"Lu","year":"1997","journal-title":"Stat Med"},{"key":"2024013019165717700_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/jbmr.5650110510","article-title":"Dual X-ray absorptiometry quality control: Comparison of visual examination and process-control charts","volume":"11","author":"Lu","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019165717700_bib15","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0378-5122(99)00064-X","article-title":"Moderation of the daily dose of HRT: Prevention of osteoporosis","volume":"33","author":"Gallagher","year":"1999","journal-title":"Maturitas"},{"key":"2024013019165717700_bib16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2003.18.1.18","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/18\/1\/18\/56472028\/5650180104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/18\/1\/18\/56472028\/5650180104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:05:45Z","timestamp":1710342345000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/18\/1\/18-23\/7592579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,1]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2003,1,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.18","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,1,1]]},"published":{"date-parts":[[2003,1,1]]}}}